Cardiology

Dermatology

Endocrinology

Hematology

Lysosomal Disorders 

Neurology

Oncology 

Ophthalmology

Home

News

Media

All Videos

Clinical Trials in Progress

ImmunoLogic

News Network

Partners

CME/CE

Conferences

Subscribe

About Us

Editorial

Contact Us

Terms and Conditions

Do Not Sell My Information

Privacy

CGTLive®

Facebook

LinkedIn

Topics

Lysosomal Disorders

Oncology

1rem

view

Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond

Videos

Experts review key updates in LBCL management from the ASH 2022 annual meeting.

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

Overview of Large B-Cell Lymphoma (LBCL)

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Treatment Strategies for Patients with R/R LBCL

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

CAR T-Cell Therapy as Second-Line Treatment in LBCL 

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting.

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.  

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases. It also includes the special RX Reports series on new therapeutics and FDA approvals.

CAR T-Cell Therapy as Second-Line Treatment in LBCL

EP: 1.Overview of Large B-Cell Lymphoma (LBCL)

EP: 2.CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

EP: 3.Treatment Strategies for Patients with R/R LBCL

EP: 4.CAR T-Cell Therapy as Second-Line Treatment in LBCL

EP: 5.Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

EP: 6.Additional Key Data Updates from ASH 2022 on Treatment of LBCL

EP: 7.Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

EP: 8.Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

Newsletter